Skip to main content
Equibles
AGEN logo

AGEN · Agenus Inc

Track AGEN — free

Use AGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.73 -0.14 (-2.04%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the filing date of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Nov 5, 2026
Market Cap
$304.51M
Shares
45.25M
Volume · Nov 13 465.28K Avg daily vol (3M) 962.63K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.73 Open$6.97 Day$6.50–6.97 52W close$2.77–9.93 Avg vol 30d793K Short int7.6M · 16.8% of shares · 10.7d Short vol62% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Next earnings call
Feb 2, 2027 Est · unconfirmed · in 11 wks
Q2 2025 earnings call transcript
call held Aug 27, 2025

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going concern raises doubt despite BOT/BAL trial plan

Agenus plans ROBBIN, a global Phase 3 trial of neoadjuvant BOT/BAL in Stage II and Stage III MSS colon cancer. Substantial doubt exists about going concern; existing resources are expected to fund operations through the third quarter of 2027.

Revenue $31.49M ▲ 4.1% Net income $2.73M ▼ 95.7% Diluted EPS $0.02 ▼ 99.0%
Read from the MD&A section
4 source passages
ROBBIN is a planned global randomized Phase 3 trial evaluating neoadjuvant BOT/BAL followed by standard of care versus standard of care alone in previously untreated high-risk Stage II and Stage III MSS colon cancer. Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the filing date of this Quarterly Report on Form 10-Q. Based on our current operating plan and projections, including scheduled debt payments in the look-forward period (the majority of which is secured by certain real estate properties), we believe our existing cash and cash equivalents, which include the net proceeds from the Private Placement, are expected to fund operations and capital expenditure requirements through the third quarter of 2027, assuming no exercise of the Series A or Series B Warrants. Agenus discontinued financial support for the BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer, after which CCTG formally terminated the study. Open the document at this passage
Nov 5
Current report 8-K
Armenia Grants First Botvymo and Evamplix Authorizations as ROBBIN Advances

Agenus Inc. reported third-quarter revenue of $31.5 million and operating income of $11.4 million. Armenia granted the first worldwide marketing authorizations for Botvymo® and Evamplix®, while ROBBIN is targeted to enroll its first patient in Q1 2027.

Financial results
4 source passages
Total revenue for the third quarter of 2026 was $31.5 million, compared with $30.2 million for the third quarter of 2025 Operating income was $11.4 million for the third quarter, the third consecutive quarter of positive operating income Shortly after quarter-end, Armenia’s Ministry of Health granted marketing authorizations for Botvymo® (botensilimab) and Evamplix® (balstilimab) Q1 2027: ROBBIN Phase 3 initiation and first patient enrollment Open the document at this passage
Oct 20
Investor event
Chardan’s 10th Annual Healthcare Investor Conference

Agenus moved to Robin as its sole registration-enabling trial; enrollment of the 60th patient is anticipated in Q2 2027, triggering warrants to generate 85 million of additional co-seeds if all exercised. A pathologic response readout is anticipated in Q4.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$133.95M
Trailing 12 months
Net income (TTM)
$30.75M
Trailing 12 months
Revenue growth YoY
+4.1%
Year over year
Operating margin
38.9%
Trailing 12 months
P / E (TTM)
6.0
Trailing earnings · reciprocal yield 16.6%
FCF yield
-34.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$57.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+153.4%
Year over year · more shares
Price change (1Y)
+55.4%
Trailing year
Short interest
16.8%
Latest settlement · 10.7 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼68% $26.84M −$46.81M '24 Q4* ▼14.1% $24.07M −$26.37M '25 Q1 ▲9.3% $25.69M −$30.01M '25 Q2 ▲20.4% $30.23M $63.91M '25 Q3 ▲27.5% $34.20M −$10.61M '25 Q4* ▲40.2% $33.74M $39.21M '26 Q1 ▲34.4% $34.52M −$567,000 '26 Q2 LATEST ▲4.1% $31.49M $2.73M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +32%
above
Price vs 50-day avg −9%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 55%
mid-range
Momentum
relative strength
Very Strong
1-month return +11%
trailing
6-month return +103%
trailing
YTD return +114%
this year
Relative strength +102%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
101 of 106 funds reported for Sep 30 · net +4.2M sh shares · +28 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.79% of shares out · ▲ +8.5% MoM · 10.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
106 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Strong
Revenue growth +90%
Y/Y
EPS growth +100%
Y/Y
Free cash flow $-77.2M
Valuation P/E 10.3
below peers
Balance sheet $41.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 121%
annualized · 1-yr
Max drawdown −41%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Mar 14, 2024
Cash proceeds from monetizing non-strategic assets, royalty mone · not stated $100M – $200M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+32% Bullish
Price vs 50-day avg
−9% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
55% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
101 of 106 funds reported for Sep 30 · net +4.2M sh shares · +28 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.79% of shares out · ▲ +8.5% MoM · 10.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
106 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $7 · 55% Range high $10
vs 200-day avg +32% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AGEN
Agenus Inc
this stock
$304.51M +114.3% +89.9% 10.3 16.8%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
120
% held
41.0%
Reported
101 of 106
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
91
View
Short & Settlement
Short Interest Rising
Shares short
7.6M
Days to cover
10.7d
Change
+593.1K sh
View
Short Volume
Short vol %
62%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
23
Value
$200
As of
Sep 23, 2026
View
Off-Exchange
Off-exchange %
44.6%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$114.2M
Net income (FY)
$-3.1M
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
27

Agenus plans ROBBIN, a global Phase 3 trial of neoadjuvant BOT/BAL in Stage II and Stage III MSS colon cancer. Substantial doubt exists about going concern; existing resources are expected to fund operations through the third quarter of 2027.

View
Proposed Sales
Value
$12.6M
Shares
786.8K
Filed
Aug 29, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Agenus Reports More Than Half of…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
AGEN -5.9% +11.4% +102.7% -1.6% +114.3%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -8.5% +12.6% +102.2% -1.4% +103.7%
Key facts CIK 1098972 CUSIP 00847G804 13F (30d) 95 filings 82 filers Visit website Investor relations